Meyka AI API is live for developers.Start building.
Advertisement
HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics, Inc. (HTGM) Stock Competitors & Peer Comparison

See (HTGM) competitors and their performances in Stock Market.

HTGMNASDAQ
HealthcareMedical - Diagnostics & Research
$0.48
$0.00(0.00%)
U.S. Market opens in NaNh NaNm
Advertisement

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
HTGM$0.48+0.00%1.1M-0.03-$17.10N/A
DHR-PB$1,261.26-0.78%916.8B146.01$8.64+0.73%
TMO$475.37+0.30%179.1B26.53$18.17+0.37%
DHR$185.09+3.94%132B36.15$5.16+0.73%
IDXX$562.27+0.27%44.5B41.49$13.61N/A
A$136.24-0.85%39.1B27.84$4.97+0.54%
NTRA$219.35+3.54%31.8B-137.10-$1.62N/A
IQV$185.78+2.05%31.2B23.19$8.06N/A
ILMN$162.47-4.95%25.4B30.50$5.51N/A
WAT$369.80-2.63%24.5B47.83$7.87N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

HTGM vs DHR-PB Comparison June 2026

HTGM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HTGM stands at 1.1M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, HTGM is priced at $0.48, while DHR-PB trades at $1,261.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HTGM currently has a P/E ratio of -0.03, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, HTGM's ROE is -2.73%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, HTGM is less volatile compared to DHR-PB. This indicates potentially lower risk in terms of short-term price fluctuations for HTGM.Check DHR-PB's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions